Primary Immunodeficiencies
July delivered a broad range of important updates in immunology, spanning regulatory approvals, new therapeutic formulations, and key clinical trial results across autoimmune, inflammatory, and rare diseases. This monthly roundup highlights the most significant developments, including first-in-class oral therapies, expanded paediatric indications, and both positive and negative late-phase trial outcomes.
Watch consultant immunologists Dr Dalm and Dr Chandra outline what APDS is, the common features of this disease and option for diagnosis, treatment and management.
Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.
What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career doctors ready to think beyond the bedside and explore the business of medicine.
In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.
We were delighted to meet with Kelli Williams (Department of Pediatrics, Medical University of South Carolina, Charleston, SC, USA) to discuss the current hot topics in pediatric immunodeficiency. The talk entitled 'Hot Topics in Pediatric Immunodeficiency' was presented as part ...
It was a pleasure to speak with Bob Geng (University of California, San Diego, CA, USA) to discuss study results investigating subcutaneous human immunoglobulin 16.5% in patients with primary immunodeficiencies. The abstract entitled 'Long-Term Safety, Efficacy, and Tolerability of Subcutaneous Human ...
It was a pleasure to speak with Bob Geng (University of California, San Diego, CA, USA) to give us an overview of immunoglobulin replacement therapy, and subcutaneous human IgG 16.5% in patients with immunodeficiencies. The abstract entitled 'Long-Term Safety, Efficacy, and ...
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
